Search

Pacific Biosciences of California Inc

Suletud

SektorTervishoid

1.95 -1.02

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.79

Max

2.08

Põhinäitajad

By Trading Economics

Sissetulek

23M

-30M

Müük

1.6M

41M

Aktsiakasum

-0.11

Kasumimarginaal

-72.9

Töötajad

485

EBITDA

2.5M

-36M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+26.32% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

11. veebr 2027

Turustatistika

By TradingEconomics

Turukapital

4.7M

734M

Eelmine avamishind

2.97

Eelmine sulgemishind

1.95

Pacific Biosciences of California Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. nov 2026, 21:01 UTC

Pacific Biosciences of California, Inc. shares fell sharply, extending a downward trend with cumulative returns down significantly since Wednesday's close.

11. nov 2026, 23:01 UTC

Pacific Biosciences of California, Inc. is trading higher in after-market hours, maintaining a cumulative return since Wednesday's close amid a broader market rise.

10. nov 2026, 22:01 UTC

News

Pacific Biosciences announces a sales agreement with Allen & Co. for up to $100 million in common stock through an at-the-market equity offering program.

9. nov 2026, 21:03 UTC

Pacific Biosciences is advancing sharply, reaching its highest cumulative return since Friday, despite initial volatility earlier in the session.

7. nov 2026, 00:01 UTC

Pacific Biosciences of California, Inc. shares are trading modestly lower in after-market hours, continuing a trend of lower closes over the past three sessions.

6. nov 2026, 23:41 UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, marking its fourth consecutive session of declines.

5. nov 2026, 23:36 UTC

Correlated Moves
News

ARK Genomic Revolution ETF declined in after-market trading as several holdings reported larger-than-expected net losses, with Pacific Biosciences also falling modestly.

4. nov 2026, 23:31 UTC

News

Pacific Biosciences reports Q3 revenue of $40.6 million, exceeding expectations, and narrows 2026 revenue guidance to $155 million to $160 million.

3. nov 2026, 23:41 UTC

Pacific Biosciences is advancing in after-market trading, supported by positive economic indicators and a broadly higher market, despite mixed earnings from Apple.

2. nov 2026, 23:11 UTC

Pacific Biosciences of California, Inc. is seeing notable strength in after-market trading, recovering from a low point shortly after the market closed.

31. okt 2026, 00:01 UTC

In after-market trading, Pacific Biosciences of California, Inc. has advanced sharply since Friday's close, remaining well above its 20-day moving average.

30. okt 2026, 23:41 UTC

Pacific Biosciences is advancing in after-market trading, reaching a high that significantly exceeds Friday's close and is well above its 20-day moving average.

29. okt 2026, 23:01 UTC

Correlated Moves

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting a broader market decline influenced by disappointing earnings from Illumina.

28. okt 2026, 23:02 UTC

Pacific Biosciences of California, Inc. is trading lower in after-market hours, reflecting the broader market's decline following the Fed's interest rate decision.

27. okt 2026, 23:06 UTC

Pacific Biosciences of California, Inc. is trading modestly lower in after-market hours, continuing a downward trend despite strong performance over the past month.

26. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, retracing from an earlier gain, despite a strong one-month performance.

23. okt 2026, 19:16 UTC

Pacific Biosciences of California Inc is trading roughly flat, showing little change since Thursday's close, while remaining below its 20-day moving average.

22. okt 2026, 19:56 UTC

Correlated Moves

Pacific Biosciences of California Inc shares fell, influenced by declines in the ARK Genomic Revolution ETF and its holdings, including 10X Genomics and Illumina.

21. okt 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours, marking its fifth consecutive session of gains.

20. okt 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours following Tuesday's close, amid ongoing volatility within its one-month trading range.

19. okt 2026, 20:07 UTC

News

Pacific Biosciences announces a multi-year collaboration with Verily Health to integrate HiFi sequencing technology with Verily's AI platform for clinico-genomic datasets.

16. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc is effectively unchanged in after-market trading, having retraced from earlier highs amid recent declines below its 20-day moving average.

15. okt 2026, 23:02 UTC

Correlated Moves

After-market hours, the ARK Genomic Revolution ETF (ARKG) is trading higher, supported by a Neutral rating for CRISPR Therapeutics from UBS and gains in key holdings.

14. okt 2026, 23:21 UTC

Pacific Biosciences shares declined in after-market trading, marking the fourth consecutive session of lower prices, reaching a recent low shortly before the latest timestamp.

13. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc's shares were roughly flat in after-market trading, following three consecutive lower daily closes while remaining above the 20-day moving average.

12. okt 2026, 22:16 UTC

Pacific Biosciences of California Inc is trading roughly flat in after-market hours, with the stock positioned around the middle of its one-month range.

9. okt 2026, 20:07 UTC

News

UBS initiated coverage of Pacific Biosciences with a Neutral rating and a price target of $1.35, adjusting its Fair Value estimate to $2.40 per share.

8. okt 2026, 23:20 UTC

Pacific Biosciences shares declined significantly in after-market trading, reversing earlier gains and marking a notable drop compared to Thursday's close.

7. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc declined during after-market hours on Wednesday, retracing significantly from its prior close despite strong recent performance.

6. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc declined in after-market trading, moving lower since Tuesday's close, despite strong performance over the past month.

Võrdlus sarnastega

Hinnamuutus

Pacific Biosciences of California Inc Prognoos

Hinnasiht

By TipRanks

26.32% tõus

12 kuu keskmine prognoos

Keskmine 2.64 USD  26.32%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pacific Biosciences of California Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

2

Osta

2

Hoia

1

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat